Investor Presentaiton

Investor presentation First three months of 2017 Slide 106 Modern insulin and VictozaⓇ comprise more than 60% of total sales in the first three months of 2017 Reported sales split by product segments for the first three months of 2017 New Generation Insulin Modern Insulin Human Insulin Other Diabetes and Obesity Care Reported sales split by selected key products for the first three months of 2017 Reported currencies Sales (mDKK) Sales split GLP-1 Diabetes Haemophilia Other Biopharmaceuticals changing diabetes Human Growth Hormone 2% 6% 6% 9% 4% 42% 20% 9% Sales of DKK 28.5 billion (+5%) TresibaⓇ 1,491 6% LevemirⓇ 4,012 14% NovoRapidⓇ 5,314 19% NovoMix® 2,766 10% VictozaⓇ 5,750 20% SaxendaⓇ 539 2% Diabetes and obesity care¹ 23,761 84% NovoSevenⓇ 2,311 8% NorditropinⓇ 1,646 6% Biopharmaceuticals¹ 4,691 16% Total¹ 28,452 100% 1 Values are higher than the sum of the total elements listed due to residual values from products not listed novo nordisk

View entire presentation